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Abstract
The nasopharyngeal commensal bacteria Streptococcus pneumoniae is also a frequent cause of serious infections.
Nasopharyngeal colonisation with S. pneumoniae inhibits subsequent re-colonisation by inducing Th17-cell adaptive
responses, whereas vaccination prevents invasive infections by inducing antibodies to S. pneumoniae capsular
polysaccharides. In contrast, protection against invasive infection after nasopharyngeal colonisation with mutant S.
pneumoniae strains was associated with antibody responses to protein antigens. The role of colonisation-induced Th17-cell
responses during subsequent invasive infections is unknown. Using mouse models, we show that previous colonisation
with S. pneumoniae protects against subsequent lethal pneumonia mainly by preventing bacteraemia with a more modest
effect on local control of infection within the lung. Previous colonisation resulted in CD4-dependent increased levels of
Th17-cell cytokines during subsequent infectious challenge. However, mice depleted of CD4 cells prior to challenge
remained protected against bacteraemia, whereas no protection was seen in antibody deficient mice and similar protection
could be achieved through passive transfer of serum. Serum from colonised mice but not antibody deficient mice promoted
phagocytosis of S. pneumoniae, and previously colonised mice were able to rapidly clear S. pneumoniae from the blood after
intravenous inoculation. Thus, despite priming for a Th17-cell response during subsequent infection, the protective effects
of prior colonisation in this model was not dependent on CD4 cells but on rapid clearance of bacteria from the blood by
antibody-mediated phagocytosis. These data suggest that whilst nasopharyngeal colonisation induces a range of immune
responses, the effective protective responses depend upon the site of subsequent infection.
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Introduction
Streptococcus pneumoniae is the second commonest cause of fatal
bacterial infection worldwide. Most deaths are due to pneumonia,
which when severe is often associated with septicaemia. Nasopha-
ryngeal colonisation with S. pneumoniae is nearly universal in infants,
with carriage rates reaching 90% [1] but then rapidly falling to 10%
in late childhood and adults [2]. S. pneumoniae pneumonia results
from aspiration of colonising bacteria from the nasopharynx into
the lungs. Infants and the elderly are particularly susceptible to
S. pneumoniae pneumonia, causing an estimated 826,000 deaths
annually in children under five years of age worldwide [3] and with
an incidence of at least 50 per 100,000 in the elderly in developed
countries [4]. S. pneumoniae septicaemia is also commoner in these
age groups and has a high mortality [5]. Infants often have a
primary septicaemia with no associated pneumonia, whereas in
adultssepticaemiausuallydevelopsasacomplicationofpneumonia.
The reasons for the changing susceptibility to S. pneumoniae disease
with age are not fully understood. Infants and the elderly are
routinely vaccinated with capsular polysaccharide based vaccines,
but these only protect against limited numbers of capsular serotypes
and the unconjugated vaccine used in adults is not effective against
pneumonia [6]. The conjugated vaccine used in children is effective
butexpensive, and hasmore limitedserotype coverage so itsefficacy
could be reduced by vaccine induced changes in S. pneumoniae
ecology. These limitations have stimulated interest in alternative S.
pneumoniae vaccine strategies.
Although S. pneumoniae infections are common, the majority of
colonised individuals do not develop disease suggesting there are
robust natural mechanisms ofimmunity. These will includephysical
defences and innate immune responses [7], but the proportionally
greater fall in S. pneumoniae disease rates compared to carriage rates
after the first year of life suggests adaptive immune responses also
have a role [1,8]. S. pneumoniae colonisation in humans can induce
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were previously thought to be the main mechanism of naturally
acquired adaptive immunity to invasive infection [8,9]. However, in
human models S. pneumoniae nasopharyngeal colonisation induces
mainly anti-protein rather than anti-capsular antibody responses
[10]. Furthermore, recent publications have shown that mice
colonised with mutant strains of S. pneumoniae, including unencap-
sulated strains, develop anti-protein antibody responses [11–13].
Colonisation-induced protection was not seen in MHCII
2/2 mice
[12], suggesting an important role for CD4+ helper T-cells. CD4 T-
cells may assist protective adaptive immune responses by providing
T-cell help towards B-cell antibody production and/or through
memory T-cell responses recalled during infectious challenge.
Recall responses to bacterial antigens by human T-cells implies
priming duringnaturalexposure[14].SuchcellsincludeTh17-cells,
capable ofproducinglarge amounts of thecytokines IL-17A andIL-
22 which facilitate cellular recruitment to sites of infection and
enhance the release of antimicrobial products from local epithelium
[15]. Th17 responses induced through immunisation can protect
against challenge with other respiratory pathogens including
Bordetella pertussis [16] and Mycobacterium tuberculosis [17]. S. pneumoniae
nasopharyngeal colonisation of mice is known to elicit a Th17-cell
response that assists primary clearance of S. pneumoniae from the
nasopharynx and inhibits recolonisation [18,19]. Furthermore,
nasal immunisation with killed S. pneumoniae or purified pneumo-
coccal proteins can also elicit a Th17-cell response capable of
protecting against subsequent colonisation. Whether colonisation-
induced Th17-cell responses are important for protective immunity
against invasive disease such as S. pneumoniae pneumonia is not
known.
We have used a murine model of nasopharyngeal colonisation
with wild-type S. pneumoniae followed by pneumonia challenge to
characterise the effects of colonisation on inflammatory and
adaptive immune responses during subsequent infection, and to
determine the relative contributions of antibody and Th17-cell
mediated responses to protection.
Methods
Ethics statement
Experiments were approved by the UCL Biological Services
Ethical Committee and the UK Home Office (Project Licence
PPL70/6510). Experiments were performed according to UK
national guidelines for animal use and care, under UK Home
Office licence.
Bacterial strains and culture conditions
S. pneumoniae D39 was a kind gift from James Paton, University
of Adelaide [20]. Bacteria were cultured on Columbia agar with
5% horse blood or in Todd-Hewitt broth with 0.5% yeast extract
in 5% CO2. Inocula for challenge experiments were prepared
from mid-log phase cultures and stored at 270uC as single use
aliquots.
Colonisation and infection models
CBA/Ca inbred mice were obtained from Charles River UK
Ltd. mMT mice were a kind gift from Dr Claudia Mauri, UCL,
London (UK). Mice were colonised by instillation of 10
7 cfu S.
pneumonia D39 in 10 ml PBS into the nares under light halothane
anaesthesia [12,21,22]. Control mice received 10 ml PBS alone.
To obtain nasal washes the exposed trachea was flushed caudally
with 200 ml PBS and the fluid exiting the nares collected. For the
pneumonia challenge, 10
7 cfu S. pneumonia D39 in 50 ml PBS was
instilled into the nares under deep general halothane anaesthesia
[21,23,24]. Animals were culled by exsanguination from the
femoral artery under pentobarbital anaesthesia. BALF was
collected by cannulating the exposed trachea and washing the
airways three times serially with 1 ml sterile PBS. Lungs were
collected aseptically after BAL had been performed into ice-cold
PBS, minced and homogenised with sterile PBS as previously
[21,24]. For survival experiments, animals were monitored and
culled when exhibiting previously defined features of terminal
disease [23]. For intravenous challenge, mice received 5610
6 cfu
S. pneumoniae D39 in 100 ml PBS via tail vein injection. Bacterial
cfu were calculated by counting colonies after plating serial
dilutions of target organ preparations on blood agar plates. Sera
for cytokine and flow cytometry assays were kept at 4uC before
being frozen and stored as single use aliquots at 270uC. For
passive transfer experiments, naı ¨ve mice received 225 ml fresh
pooled serum from colonised or control mice (obtained 28 days
after colonisation) by intraperitoneal injection 6 h and 30 minutes
prior to pneumonia challenge. For CD4+ cell depletion, mice
received 250 mg mAb GK1.5 (eBiosciences) intraperitoneal 48 and
24 h preceding pneumonia challenge; flow cytometric examina-
tion of splenocytes confirming successful depletion of .90% of
CD4 cells [19].
Assessment of the inflammatory response to infection
To obtain BALF cell proportions, 300 cells from random fields
of BALF cytospin preparations (Cytospin 3, Shandon) with rapid
Romanowsky stain were counted according to standard morpho-
logical criteria, and absolute counts derived from haemocytometer
cell counts. In selected experiments the degree of lung inflamma-
tion was assessed histologically. The entire left lung was fixed,
processed to paraffin wax and stained with haematoxylin and
eosin. Inflammation was assessed by a blinded observer using an
established scoring system [24]. This involved assessing the
percentage of overall lung involvement under 610 magnification,
followed by examination of 6 random fields under 620 magnifi-
cation. The composite score reported is the product of mean score
for individual areas multiplied by percentage of lung affected. Sera
and BALF supernatants cytokine levels were measured by ELISA
(IL-17, IL-22 and IFN-c, R&D Systems) or by Luminex
TM bead
immunoassay (Invitrogen) according to manufacturers’ instructions.
ELISAs for antibody responses
Antibodies specific to S. pneumoniae D39 antigens were measured
by whole cell ELISA using established methods as previously
described [25]. Briefly, S. pneumoniae D39 was grown to late log-
phase, washed and resuspended in PBS to OD580 1.0. 96-well
plates were coated with this bacterial suspension, refrigerated
overnight, then blocked with PBS 1% BSA prior to use. Sera were
diluted in PBS 1% BSA before addition and binding to bacterial
antigens detected with anti-mouse secondaries conjugated to
alkaline phosphatase (Sigma).
Flow cytometry assays of phagocytosis
Phagocytosis of FAMSE (Molecular Probes) labelled S.
pneumoniae by freshly isolated human neutrophils (MOI of 10:1)
was measured using flow cytometry to obtain the MFI for cells
associated with fluorescent bacteria as previously described [25]. In
vivo phagocytosis by alveolar macrophages was measured using a
flow cytometry method as previously described [26]. Briefly, mice
were inoculated intranasally with FAM-SE labelled 10
7 cfu D39,
BALF obtained at 4 h and analysed using flow cytometry. Alveolar
macrophages were identified based on scatter properties and
bacterial phagocytosis measured as the MFI for macrophages
associated with fluorescent bacteria.
Colonisation-Induced S. pneumoniae Protection
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Survival of challenged mice was compared by the log rank test.
Bacterial loads in BALF and lung, antibody and cytokine levels
(non-parametric) were compared by Mann-Whitney U-test.
Presence or absence of bacteraemia was compared by the Fischer
exact test. In vivo phagocytosis (parametric) were assessed by
unpaired Student t-test. In vitro neutrophil phagocytosis was
compared by one-way Anova with post-hoc tests. P values,0.05
were considered significant.
Results
S. pneumoniae colonisation model
To establish nasopharyngeal colonisation, CBA/Ca mice were
intranasally inoculated with 10
7 cfu S. pneumoniae D39 suspended in
10 ml PBS and nasopharyngeal washes and bronchoalveolar lavage
fluid (BALF) collected at 2, 11, 21 and 28 days to quantify S.
pneumoniae colonisation. S. pneumoniae were recovered in nasopha-
ryngeal washes from all mice at 2 days (median 5.68610
3 cfu/ml,
interquartile range (IQR) 2.87–12.0), 80% of mice at 11 days
(median 1.4610
3 cfu/ml IQR 0.16–3.66), but from no mice on
days 21 and 28 (Fig. 1). Furthermore, no bacteria were recovered
from homogenates of nasopharyngeal tissue harvested on day 21
(n=6). On occasion a few S. pneumoniae colonies were recovered
from BALF (#50 cfu/ml), but no bacteria were recovered from
lung homogenates or blood at any timepoint.
Prior colonisation protects against lethal S. pneumoniae
pneumonia by preventing bacteraemia
To investigate whether previous colonisation can induce
adaptive mechanism(s) that protect against lethal infection, a
model of rapidly developing fatal pneumonia was used in which
mice were inoculated intranasally with 10
7 cfu S. pneumoniae D39
suspended in 50 ml PBS. When challenged 28 days following
colonisation, previously colonised mice were highly protected. All
mice in the control group (which were sham colonised by
intranasal administration of PBS) developed fatal infection with
a median survival of 30 h whereas 94% of colonised mice survived
(P,0.0001) (Fig. 2A). To further characterise colonisation-induced
protection, groups of colonised or control mice given a day 28
pneumonia challenge were sacrificed at 4, 9 and 18 h to quantify
the bacterial load in blood, BALF and lung (Fig. 2B–2D). In
control mice there were significant numbers of bacteria in both
BALF and lungs at all timepoints, and in the blood at 9 and 18 h.
In colonised mice there were similar numbers of bacteria in BALF
to controls at all timepoints and in the lungs at 4 and 9 h. By 18 h,
there were approximately 1-log fewer bacteria in the lungs of
previously colonised mice than controls. Strikingly, at both 9 and
18 h post-challenge no bacteria were recovered from the blood of
colonised mice, demonstrating that protection against fatal
pneumonia in colonised mice was associated with the prevention
of detectable bacteraemia.
Previous colonisation primes for greater mucosal and
systemic IL-17 responses
To characterise the effect of previous colonisation on the
inflammatory response during S. pneumoniae pneumonia, BALF
cytokine levels were measured at 4 and 18 h after pneumonia
challenge (Figure 3A, 3B). Compared to controls, in previously
colonised mice there were modest but statistically significant
increases in BALF levels of several innate cytokines, including
TNF-a and IL-6, at 4 h but not at 18 h. In addition, at 18 h, IL-
17 and IL-22 were markedly higher in BALF from previously
colonised mice compared to controls, and IL-17 was also
significantly higher in the serum (Figure 3C). Colonisation also
primed for greater BALF neutrophil recruitment compared to
controls at 4 h (mean 2.260.4610
5/ml versus 1.160.73610
6/ml,
P=0.02) but not at 9 h (mean 1.9461.57610
6/ml versus
1.3360.94610
6/ml, P=0.43) (Fig. 4A, 4B). Hence, in previously
colonised mice there was a modest increase in the strength of the
early inflammatory response to subsequent S. pneumoniae lung
infection and potentially significant mucosal and systemic Th17
responses. However, histological assessment of lung sections
obtained 18 h after inoculation demonstrated there were no
detectable differences in lung inflammation scores between
colonised and control mice in established pneumonia (mean score
2.1060.77 versus 1.6160.59, P=0.24) (Fig. 4C).
CD4 cells were not required for colonisation induced
protection against bacteraemia
Th17-cell mediated immunity assists nasopharyngeal clearance
of S. pneumoniae [19], and the enhanced IL-17 response to
pneumonia in previously colonised mice suggest a Th17 response
might be contributing towards protection against invasive disease.
To investigate this possibility, colonisation and subsequent S.
pneumoniae pneumonia challenge experiments were repeated in
mice depleted of CD4+ cells immediately before challenge using
anti-CD4 antibody. CD4 depletion (.90% efficacy) abolished the
colonisation-induced enhancement of BALF IL-17 levels at
18 hours in response to S. pneumoniae pneumonia in previously
colonised mice (Figure 5A). Furthermore, in the absence of CD4
cells, no IL-17 was detected in the serum following infection of
either colonised or control mice (data not shown). These data
suggest that colonisation-induced Th17-cells were the source of the
enhanced mucosal and systemic IL-17 responses observed in
colonised mice.
In the absence of CD4 cells, 42% of challenged control mice
developed significant bacteraemia by 18 h following challenge
(Figure 5B). Nevertheless, even in the absence of Th17 cell
responses, colonised mice were still fully protected against
bacteraemia (P=0.037). In addition, there were still fewer bacteria
in the lungs of colonised than control mice despite the absence of
CD4 T-cells. Thus, the enhanced CD4-cell dependant IL-17
response to subsequent pneumonia in colonised mice does not
seem to be required for protection in this model.
Figure 1. S. pneumoniae D39 colonises the nasopharynx of CBA/
Ca mice. Bacterial cfu recovered from nasal washes and BALF 2, 11 and
28 days following intranasal inoculation in 10 ml of PBS with 10
7 cfu D39
S. pneumoniae. Each dot represents results for an individual mouse and
bars the median for each group. The dotted line is the limit of
detection.
doi:10.1371/journal.pone.0025558.g001
Colonisation-Induced S. pneumoniae Protection
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25558Colonisation induces a protective antibody response
The continued colonisation-induced protection in CD4 deplet-
ed mice demonstrated there must be alternative mechanisms of
protection to Th17 responses, suggesting a role for colonisation-
induced antibody. We therefore assessed antibody responses to S.
pneumoniae colonisation in our model. Whole cell ELISAs detected
high levels of serum IgG against D39 antigens in nearly all
colonised mice 28 days after colonisation (Fig. 6A). Only a small
number of colonised mice had serum IgA or IgM responses greater
than controls (Fig. 6B, 6C). There were strong IgG and IgA
responses to D39 evident in BALF (Fig. 6D, 6E).
To determine whether protection was dependant on the
presence of antibody, further colonisation and challenge experi-
ments were performed in mMT mice which congenitally lack
antibody. All colonised mMT mice developed bacteraemia by 18 h
following challenge (Fig. 7A). To identify whether the antibody
Figure 2. Effects of prior colonisation on progression of subsequent S. pneumoniae pneumonia. (A) Kaplan-Meier survival curves of
previously colonised or control CBA/Ca mice following pneumonia challenge with 10
7 cfu D39 S. pneumoniae in 50 ml PBS on day 28 (n=18 or 19).
(B–D) Bacterial cfu in BALF, lung or blood of colonised or control mice at (B) 4 h, (C) 9 h or (D) 18 h following pneumonia challenge. Each symbol
represents results for an individual mouse and bars the median for each group. The dotted line is the limit of detection. Significance of the difference
in bacterial numbers recovered from lungs of colonised and control mice was assessed by Mann-Whitney U-test. Significance of differences in
presence or absence of bacteraemia was assessed by Fisher exact test. Data at 18 h are pooled from two experiments with similar results.
doi:10.1371/journal.pone.0025558.g002
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subsequent pneumonia, naı ¨ve CBA/Ca mice were passively
vaccinated by intraperitoneal injection with fresh pooled sera
obtained from colonised or control CBA/Ca mice, then given a
pneumonia challenge. The anti-D39 whole cell IgG titre of donor
serum was 1/2260, and achieved a mean titre in the serum of
passively immunised mice of 1/30961/110. Compared to recipients
of control serum, passively immunised mice had significantly fewer
bacterialCFUrecoveredfromthelungsat18 h.Furthermore,there
was a strong trend towards prevention of bacteraemia, with only 1
of 6 recipients of immune serum developing bacteraemia compared
to 5 of 6 recipients of control serum by 18 h post-pneumonia
challenge (Fig. 7B), similar to the data obtained with actively
colonised mice (Fig. 2B–2D). Overall, these data demonstrate that
the systemic antibody response to S. pneumoniae colonisation is both
necessary and sufficient to protect, and that whilst colonisation
induces a Th17 cell response, this is not required.
Enhanced S. pneumoniae phagocytosis in serum from
previously colonised mice
To further characterise the mechanism of antibody mediated
protection in colonised mice, flow cytometry assays were used to
assess the impact of colonisation-induced serum antibody on
neutrophil association with live S. pneumoniae. Incubation of 6-
carboxyfluorescein succinimidyl ester (FAMSE) labelled D39 with
serum from colonised CBA/Ca mice resulted in enhanced
association with human neutrophils (known to be mainly due to
phagocytosis [27] compared to serum from control CBA/Ca mice
(Fig. 8A). No differences in phagocytosis were observed when
bacteria were incubated in sera from colonised or control mMT
Figure 3. Effect of prior colonisation on cytokine levels during subsequent pneumonia. BALF samples were collected at either (A) 4 h or
(B) 18 h and serum (C) at 18 h following pneumonia challenge of previously colonised (black bars) or control (white bars) CBA/Ca mice (n=6 per
group). Cytokine levels were measured by either Luminex bead assay or ELISA. Group mean + SEM are displayed. Dotted line represents limit of
detection.
doi:10.1371/journal.pone.0025558.g003
Colonisation-Induced S. pneumoniae Protection
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CBA/Ca mice bound to the S. pneumoniae surface was responsible
for the enhanced phagocytosis in this serum. In contrast, when
colonised and control mice were challenged with FAM-SE-
labelled D39 there were no differences in the association of
fluorescent S. pneumoniae with alveolar macrophages recovered
from BALF 4 h post-inoculation (Fig. 8C). Hence colonisation
resulted in improved antibody dependent phagocytosis in serum
Figure 4. Effect of prior colonisation on inflammation during subsequent pneumonia. (A–B) Numbers of neutrophils (hatched region) and
macrophages (dotted region) present in BALF of previously colonised or control CBA/Ca mice at (A) 4 h and (B) 9 h following pneumonia challenge.
Bars represent mean + SEM (n=6 mice per group). (C) Lung inflammation scores assessed by blinded histological examination of lung sections
collected 18 h following challenge of colonised or control mice. Dots represent individual mice, bars represent medians.
doi:10.1371/journal.pone.0025558.g004
Figure 5. Role of CD4+ cells in the effect of prior colonisation on subsequent pneumonia. Cytokine levels (A) and bacterial CFU (B)
recovered from colonised or control CBA/Ca mice 18 h following pneumonia challenge in the absence of CD4+ cells. Mice were depleted of CD4+
cells using GK1.5 prior to challenge. (A) Cytokine levels in BALF of colonised mice (black bars) or control mice (white bars) measured by Luminex or
ELISA. Group mean + SEM are displayed. (B) Bacterial cfu in BALF, lung and blood of colonised or control CBA/Ca. Each symbol represents results for
an individual mouse and bars the median for each group. The dotted line is the limit of detection. Significance of the difference in bacterial numbers
recovered from lungs of colonised and control mice was assessed by Mann-Whitney U-test. Significance of differences in presence or absence of
bacteraemia was assessed by Fisher exact test. Data are pooled from two experiments with similar results.
doi:10.1371/journal.pone.0025558.g005
Colonisation-Induced S. pneumoniae Protection
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in vivo. This was consistent with prior colonisation having no effect
on the number of bacteria recovered from BALF following
pneumonia, but marked protection against pneumonia-associated
bacteraemia (Fig. 2B–2D).
To investigate whether previous colonisation improved systemic
clearance of S. pneumoniae, known to be largely dependent on
phagocytosis [28], mice were inoculated intravenously with
5610
6 cfu of D39. At 2 and 5 h post-intravenous inoculation
there were over 10
4 fewer bacteria in the blood of previously
colonised mice compared to control mice (Fig. 8D), demonstrating
that colonisation promoted rapid clearance of S. pneumoniae from
the blood consistent with previous colonisation resulting in a
marked augmentation of serum-mediated phagocytosis.
Discussion
Recent data obtained using mouse models of colonisation have
emphasised the importance of Th17 responses for protection
against subsequent re-infection of the nasopharynx, and have
shown that colonisation also protects against subsequent invasive
infection. The development of protection against invasive infection
required both CD4 cells and antibody but the precise mechanisms
involved have not been clearly defined [12]. In this study, we have
investigated in detail potential mechanisms of protection against
subsequent pneumonia associated with S. pneumoniae nasopharyn-
geal colonisation. Mortality due to S. pneumoniae is mainly related to
severe infections with septicaemia. Hence, to identify protective
mechanisms that are effective against severe infection we have
deliberately chosen a disease model of fulminant infection
requiring a large inoculum with rapid spread of bacteria from
the lungs to the blood and a high mortality. Several mechanisms
through which colonisation may impact on subsequent disease
progression were identified.
Firstly, prior nasopharyngeal colonisation was associated with a
stronger mucosal inflammatory response 4 h after pneumonia
challenge, with higher levels of some cytokines and a more rapid
influx of neutrophils. The rapidity of onset of this difference
between colonised and control mice suggests that colonisation may
lead to alteration of the ‘innate immune rheostat’, priming for a
more robust response to subsequent pneumonia challenge [29].
During the time that the nasopharynx remains colonised, small
numbers of bacteria are likely to be aspirated into the lungs. These
could have effects on innate immune cells such as macrophages
and gamma-delta T-cells as shown for non-bacteraemic pneumo-
nia [30]. This could lead to more robust cytokine production early
in subsequent infection. Alternatively, mucosal antibody induced
through prior colonisation may facilitate the interaction between
bacteria and host cells such as alveolar macrophages during early
pneumonia challenge and enhance cytokine responses. However,
the effects of prior colonisation on the early inflammatory response
in the lungs did not limit the development of disease in this model.
There were no significant differences between colonised and
control mice in in vivo phagocytosis of bacteria by alveolar
macrophages, in bacterial CFU in BALF or lung, or in the
histological severity of pneumonia. Potentially, the effects of
colonisation on early inflammatory responses may have protective
effects with other less fulminant models of pneumonia using lower
inocula and / or less virulent S. pneumoniae strains.
Nasopharyngeal colonisation also primed for an enhanced lung
and systemic IL-17 response following in vivo challenge. This was
dependant on CD4-cells, strongly suggesting that it derives from a
Th17-cell response to colonisation similar to that found in
the nasopharynx following re-colonisation [19,31]. However in
contrast to the importance of a Th17-cell response for preventing
re-colonisation of the nasopharynx, colonised mice depleted of
CD4 cells were still protected against bacteraemia and still had
reduced lung CFU at 18 hours. Hence, Th17 responses are not
Figure 6. Systemic and mucosal antibody responses to colonisation. IgG (A and D), IgA (B and E) and IgM (C) responses to D39 in serum (A–
C) or BALF (D–E) obtained from colonised or control mice measured using whole cell ELISAs.
doi:10.1371/journal.pone.0025558.g006
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inability of previous colonisation to protect MHCII deficient mice
against lethal challenge [12] is likely to reflect a need for CD4 T-
cells in supporting the development of a mature antibody response
to colonisation, rather than an effector role at the time of
challenge. Rapid neutrophil recruitment occurs within the lungs
even in uncolonised control mice, and bacteraemia is established
relatively early in infection, probably eclipsing any benefits from a
Th17-cell mediated increase in phagocyte recruitment. In
contrast, recruitment of phagocytes to the nasopharynx during S.
pneumoniae colonisation is delayed unless supported by an adaptive
Th17 cell response induced by a previous colonisation event [19].
Hence a Th17 response is critical for adaptive immunity against
colonising S. pneumoniae but not for the rapidly invasive model of
pneumonia described in this mansucript.
In addition, there is some evidence that Th17 cells actually
might be deleterious during S. pneumoniae pneumonia [32,33],
possibly explaining why we found CD4 depletion was associated
with a trend towards fewer bacteria in the blood at 18 h.
Vaccination-induced Th17-cell responses may still be beneficial
for protection against a less fulminant pneumonia in which
bacteria remain within the lung.
The strongest effect of colonisation observed during challenge in
our model was the protection against bacteraemia. This suggests
protective responses either prevent spread of S. pneumoniae from the
lungs to the blood or that on reaching the blood bacteria are
rapidly cleared. Nearly all mice developed serum IgG responses to
S. pneumoniae D39 antigens, and experiments with antibody-
deficient mice demonstrated that protection against bacteraemia
was highly dependent on antibody to S. pneumoniae. Following
passive transfer of serum by intraperitoneal injection, there was a
significant reduction in the number of bacteria present in the lungs
18 h following infection. This suggests that systemic antibody can
assist control of infection within the lungs as well. Antibody to S.
pneumoniae is mainly thought to cause protection by opsonising
bacteria for phagocytosis, and in vitro phagocytosis assays and in
vivo IV clearance data confirmed that colonisation induced
antibody responses improved S. pneumoniae phagocytosis. The
strength of the effect on IV clearance was particularly striking,
reducing bacterial CFU by a factor of 3 to 4 log10, readily
explaining why colonised mice do not develop septicaemia. The
observation that colonisation prevents the development of systemic
infection provides one potential explanation for the rapid fall in
the incidence of S. pneumoniae septicaemia in older children after a
period of recurrent colonisation as infants.
Which S. pneumoniae antigens are the targets for protective
responses in our model is not clear. Both capsular and protein
antigens may induce antibody responses after murine nasopharyn-
geal colonisation [11,13]. However, colonisation with S. pneumoniae
mutant strains not able to express the capsule or seemingly im-
munodominant protein antigens were still able to induce protective
responses [13] suggesting antigens inducing protective antibody
responses are partially redundant. We are currently identifying
which antibodies dominate the immune response to colonisation in
Figure 7. Role of antibody in the effect of prior colonisation on subsequent pneumonia. (A) Bacterial cfu in BALF, lung and blood of
colonised or control mMT mice 18 h following pneumonia challenge. (B) Bacterial cfu in BALF, lung and blood of passively immunised CBA/Ca mice
18 h following pneumonia challenge. Mice received pooled serum collected from either colonised or control CBA/Ca mice prior to challenge. Each
symbol represents results for an individual mouse and bars the median for each group. The dotted line is the limit of detection. Lung cfu are
compared between groups by Mann-Whitney U-test. Presence or absence of bacteraemia was assessed by Fisher exact test.
doi:10.1371/journal.pone.0025558.g007
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25558this model, and which are the important antibodies in effecting
protection.
To conclude, we have investigated the mechanisms of protection
against subsequent pneumonia induced by nasopharyngeal coloni-
sation with S. pneumoniae. In our model although colonisation results
in a more rapid inflammatory response during early lung infection
and a significant CD4-dependent IL-17 response, neither was
necessary for the powerful protection against fulminant pneumonia
providedbypriorcolonisation.Instead,protectionwasduetoserum
antibody responses that promoted rapid clearance of S. pneumoniae
from the blood.
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Figure 8. Colonisation induces serum opsonophagocytic antibody. (A–B) Flow cytometry assays of neutrophil phagocytosis of FAM-SE
labelled D39 after incubation in serum from either (A) colonised or control CBA/Ca mice or PBS, or (B) colonised or control mMT mice or PBS. A
representative histogram is shown on the left (clear PBS, black 20% control sera, grey 20% colonised sera), and mean MFI 6 SEM (n=4 replicates) for
each condition in the graph on the right. (C) MFI of alveolar macrophages present in BALF of previously colonised or control CBA/Ca mice 4 h
following challenge with 10
7 cfu FAM-SE-labelled D39 S. pneumoniae. Dots represent individual mice, bars represent medians. (D) Numbers of cfu of
S. pneumoniae recovered from blood of colonised or control mice inoculated intravenously with 5610
6 cfu S. pneumoniae D39 (n=6 per group) at 2
and 5 h. Dots represent data from individual mice, bars represent group medians.
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